These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34764822)

  • 21. Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3.
    Zhong E; Pareja F; Hanna MG; Jungbluth AA; Rekhtman N; Brogi E
    Hum Pathol; 2022 Sep; 127():102-111. PubMed ID: 35690220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears.
    Hou T; Gan Q; Joseph CT; Sun X; Gong Y
    Cancer Cytopathol; 2020 Oct; 128(10):725-732. PubMed ID: 32573984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract.
    Kim IE; Amin A; Wang LJ; Cheng L; Perrino CM
    Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):687-693. PubMed ID: 31876605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers.
    Staaf J; Tran L; Söderlund L; Nodin B; Jirström K; Vidarsdottir H; Planck M; Mattsson JSM; Botling J; Micke P; Brunnström H
    Arch Pathol Lab Med; 2020 Sep; 144(9):1075-1085. PubMed ID: 31913660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity.
    Rooper LM; Sharma R; Li QK; Illei PB; Westra WH
    Am J Surg Pathol; 2017 Nov; 41(11):1561-1569. PubMed ID: 28719469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: Evaluation of 24 cases.
    Leblebici C; Yeni B; Savli TC; Aydın Ö; Güneş P; Cinel L; Şimşek BÇ; Yıldız P; Tuncel D; Kayahan S
    Ann Diagn Pathol; 2019 Jun; 40():53-58. PubMed ID: 31031215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. INSM1 immunostaining in solid papillary carcinoma of the breast.
    Kudo N; Takano J; Kudoh S; Arima N; Ito T
    Pathol Int; 2021 Jan; 71(1):51-59. PubMed ID: 33156579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A morphological and immunohistochemical study of ductal carcinoma in situ, invasive breast carcinoma of no special type, and mucinous carcinoma of the breast in comparison with solid papillary carcinoma regarding neuroendocrine marker expression.
    Otsuki Y; Asano Y; Ikeya T; Ishida Y; Sezaki S; Kobayashi H
    Virchows Arch; 2024 Sep; 485(3):547-555. PubMed ID: 38958708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroendocrine Markers Insulinoma-Associated Protein 1, Chromogranin, Synaptophysin, and CD56 Show Rare Positivity in Adenocarcinoma Ex-Goblet Cell Carcinoids.
    Yang C; Gonzalez I; Zhang L; Cao D
    Gastroenterology Res; 2019 Jun; 12(3):120-127. PubMed ID: 31236152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine differentiation in a large series of genetically-confirmed Ewing's sarcoma family tumor: Does it provide any diagnostic or prognostic information?
    Machado I; Navarro S; López-Guerrero JA; Verdini L; Picci P; Giner F; Llombart-Bosch A
    Pathol Res Pract; 2021 Mar; 219():153362. PubMed ID: 33610950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases.
    Kendall Bártů M; Němejcová K; Michálková R; Bui QH; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Šafanda A; Singh N; Škapa P; Špůrková Z; Stolnicu S; Švajdler M; Lax SF; McCluggage WG; Dundr P
    Int J Gynecol Pathol; 2024 Mar; 43(2):123-133. PubMed ID: 37406366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.
    Baykara Y; Xiao Y; Yang D; Yakirevich E; Maleki S; Garcia-Moliner M; Wang LJ; Huang CK; Lu S
    Virchows Arch; 2022 Jul; 481(1):31-39. PubMed ID: 35357570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SOX11 is a sensitive and specific marker for pulmonary high-grade neuroendocrine tumors.
    Yu L; Dong Y; Xue J; Xu S; Wang G; Kuang D; Duan Y
    Diagn Pathol; 2022 Jan; 17(1):2. PubMed ID: 34996493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulinoma-associated protein 1 (INSM1) expression in breast carcinomas with neuroendocrine morphologies: application and future prospective.
    Kawasaki T; Kaira K
    Virchows Arch; 2021 Jul; 479(1):191-194. PubMed ID: 33025295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosensitivity and specificity of insulinoma-associated protein 1 (INSM1) for neuroendocrine neoplasms of the uterine cervix.
    Kuji S; Endo A; Kubota M; Uekawa A; Kawakami F; Mikami Y; Koike J; Suzuki N
    J Gynecol Oncol; 2023 Jan; 34(1):e1. PubMed ID: 36245222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. INSM1 expression in primary and metastatic neuroendocrine neoplasms at distinct locations.
    Wang XQ; Fu J; Zhang YT; Xu Y
    Pathol Res Pract; 2024 Jan; 253():155067. PubMed ID: 38171081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.
    González I; Lu HC; Sninsky J; Yang C; Bishnupuri K; Dieckgraefe B; Cao D; Chatterjee D
    Histopathology; 2019 Oct; 75(4):568-577. PubMed ID: 31077609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
    Hacking SM; Yakirevich E; Wang Y
    J Pathol Clin Res; 2023 Jul; 9(4):313-321. PubMed ID: 37082801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulinoma-associated protein 1 (INSM1): a potential biomarker and therapeutic target for neuroendocrine tumors.
    Mahalakshmi B; Baskaran R; Shanmugavadivu M; Nguyen NT; Velmurugan BK
    Cell Oncol (Dordr); 2020 Jun; 43(3):367-376. PubMed ID: 32219703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neuroendocrine expression markers in triple-negative, luminal-A, luminal-B and HER2neu breast cancer].
    Barboza-García YG; Ramírez-Balderrama L; Murguía-Pérez M; Hernández-González MA; Landeros-Navarro IY
    Rev Med Inst Mex Seguro Soc; 2024 Jan; 62(1):1-7. PubMed ID: 39110839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.